Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study

Gris, Jean‐Christophe; Perneger, Thomas; Quéré, Isabelle; Mercier, É.; Fabbro‐Peray, Pascale; Lavigne-Lissalde, Géraldine; Hoffet, M.; Déchaud, H.; Boyer, Jean-Christophe; Ripart-Neveu, Sylvie; Tailland, Marie-Laure; Daurès, Jean‐Pierre; Marès, P.; Dauzat, M.

doi:10.1182/blood-2003-01-0320

Cited by 84 publications

(66 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To address these discrepant findings we have further analyzed FV activity levels and FV genotype in a large cohort of subjects from Northern Italy [3]. By genotyping this…”

Section: Acknowledgementsmentioning

confidence: 99%

Diffuse skin necrosis in a patient with an anti‐endothelial cell protein C receptor autoantibody which blocks protein C activation

Lavigne-Lissalde¹,

Cochery-Nouvellon²,

Granier

et al. 2005

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

“…To address these discrepant findings we have further analyzed FV activity levels and FV genotype in a large cohort of subjects from Northern Italy [3]. By genotyping this…”

Section: Acknowledgementsmentioning

confidence: 99%

Diffuse skin necrosis in a patient with an anti‐endothelial cell protein C receptor autoantibody which blocks protein C activation

Lavigne-Lissalde¹,

Cochery-Nouvellon²,

Granier

et al. 2005

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

“…7 Briefly, LAs were detected using the following screening assays: activated partial thromboplastin time (aPTT; PTT LA, Stago), dilute Russell viper venom time (Bioclot LA; Biopool), and tissue thromboplastin inhibition test using a 1:500 thromboplastin dilution (Neoplastin CI Plus; Stago). LAs were first identified in samples that were mixed 1:1 with healthy pooled plasma and were then confirmed by neutralization procedures according to the recommendations of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis.…”

Section: Assaysmentioning

confidence: 99%

Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study

Gris

Bouvier

Molinari³

et al. 2012

Blood

Self Cite

103

View full text Add to dashboard Cite

The incidence of thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain. We performed a 10-year observational study of 1592 nonthrombotic women who had experienced 3 consecutive spontaneous abortions before the 10th week of gestation or 1 fetal death at or beyond the 10th week of gestation. We compared the frequencies of thrombotic events among women positive for antiphospholipid Abs (n ‫؍‬ 517), women carrying the F5 6025 or

show abstract

“…infra). 9,10 Women with antithrombin, protein C, or protein S deficiency, and women with an abnormal fibrinogen or the JAK2 V617F mutation were not included. Women with completely negative thrombophilia screening results (N 5 3741) and who agreed to participate in the observational study (n 5 3604) were provisionally assigned to the "negative" group and were numbered according to the order in which they entered the study.…”

Section: Introductionmentioning

confidence: 99%

Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study

Bouvier

Cochery-Nouvellon

Lavigne-Lissalde

et al. 2014

Blood

Self Cite

147

116

View full text Add to dashboard Cite

Key Points• Among women with pure obstetric APS, late pregnancy complications are more frequent in cases of prior fetal loss.• Late pregnancy complications are more frequent among women treated for pure obstetric APS than among nontreated controls.The incidence of pregnancy outcomes for women with the purely obstetric form of antiphospholipid syndrome (APS) treated with prophylactic low-molecular-weight heparin (LMWH) plus low-dose aspirin (LDA) has not been documented. We observed women without a history of thrombosis who had experienced 3 consecutive spontaneous abortions before the 10th week of gestation or 1 fetal loss at or beyond the 10th week.We compared the frequencies of complications during new pregnancies between treated women with APS (n 5 513; LMWH 1 LDA) and women negative for antiphospholipid antibodies as controls (n 5 791; no treatment). Among APS women, prior fetal loss was a risk factor for fetal loss, preeclampsia (PE), premature birth, and the occurrence of any placenta-mediated complication. Being positive for anticardiolipin immunoglobulin M antibodies was a risk factor for any placenta-mediated complication. Among women with a history of recurrent abortion, APS women were at a higher risk than other women of PE, placenta-mediated complications, and neonatal mortality. Among women with prior fetal loss, LMWH 1 LDA-treated APS women had lower pregnancy loss rates but higher PE rates than other women. Improved therapies, in particular better prophylaxis of late pregnancy complications, are urgently needed for obstetric APS and should be evaluated according to the type of pregnancy loss. (Blood. 2014;123(3):404-413)

show abstract

Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study

Cited by 84 publications

References 40 publications

Diffuse skin necrosis in a patient with an anti‐endothelial cell protein C receptor autoantibody which blocks protein C activation

Diffuse skin necrosis in a patient with an anti‐endothelial cell protein C receptor autoantibody which blocks protein C activation

Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study

Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study

Contact Info

Product

Resources

About